Effects of rosuvastatin on Bcl-2 and Bax expressions in aorta of rats with hyperhomocysteinemia

ZHANG Zhengjun,JIA Shaobin,LIU Jing,HOU Jianjun,WANG Hao,LI Lu
DOI: https://doi.org/10.11699/cyxb20130821
2013-01-01
Abstract:Objective:To investigate the effects of rosuvastatin on expressions of B cell leukemia/lymphoma-2(Bcl-2) and Bcl-2-associated X protein(Bax) in aortas of Wistar rats with hyperhomocysteinemia(Hhcy).Methods:Serum triglyceride,total cholesterol,low density lipoprotein-cholesterol and plasma homocysteine(Hcy) concentrations were detected by ADVIA2400 automatic biochemical analyzer,pathological changes of aorta were observed by HE staining and Bcl-2 and Bax expressions of aortic tissues were detected by immunohistochemistry and RT-qPCR detection.Results:Plasma Hcy concentration was lower in rosuvastatin group than in Hhcy group,(10.47±0.07) μmol/L vs.(85.38±0.2) μmol/L,with statistically significant differences(P<0.05).Aortic injury was less severe in rosuvastatin group than in Hhcy group.Immunohistochemistry demonstrated that Bcl-2 protein expressions were lower in rosuvastatin group than in Hhcy group and Bax protein expressions were higher in rosuvastatin group than in Hhcy group,with statistically significant differences(P<0.05).RT-qPCR assay showed Bcl-2 mRNA was decreased in rosuvastatin group than in Hhcy group and Bax mRNA was increased in rosuvastatin group than in Hhcy group(P<0.05).Conclusions:Rosuvastatin can delay Hhcy rat aortic atherosclerosis hardening process through decreasing plasma Hcy concentration and influencing aortic tissue Bcl-2 and Bax gene expressions.
What problem does this paper attempt to address?